Puesta al día en hipertensión pulmonar
Resumen
En la práctica cardiológica en Cuba son frecuentemente referidos pacientes con sospecha clínica de hipertensión pulmonar, el mayor porcentaje de los casos para confirmación diagnóstica, definición de causas y abordaje terapéutico. El criterio para definirla es una presión media en la arteria pulmonar mayor de 25 mmHg. La enfermedad puede presentarse en distintos procesos clínicos, que se clasifican en 5 grupos. En este artículo se muestra una revisión de la bibliografía y las publicaciones más recientes acerca de este tema.
Descargas
Citas
1. Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37(1):67-119. DOI: https://doi.org/10.1093/eurheartj/ehv317
2. Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J [Internet]. 2019 [citado 10 Ene 2021];53(1):1801913. Disponible en: https://doi.org/10.1183/13993003.01913-2018
3. Barber? JA, Román A, Gómez-Sánchez MA, Blanco I, Otero R, López-Reyes R, et al. Diagnóstico y tratamiento de la hipertensión pulmonar (Normativa SEPAR) [Internet]. Barcelona: Editorial Respira [citado 10 Ene 2021]; 2017. Disponible en: https://www.sogapar.info/wp-content/uploads/2016/12/7-Normativa-SEPAR-hipertension-pulmonar.pdf
4. Portillo K, Santos S, Madrigal I, Blanco I, Pare C, Borderias L, et al. Study of the BMPR2 gene in patients with pulmonary arterial hypertension. Arch Bronconeumol. 2010;46(3):129-34. DOI: https://doi.org/10.1016/j.arbres.2009.11.005
5. Pousada G, Baloira A, Vilariño C, Cifrian JM, Valverde D. Novel mutations in BMPR2, ACVRL1 and KCNA5 genes and hemodynamic parameters in patients with pulmonary arterial hypertension. PLoS One [Internet]. 2014 [citado 12 Ene 2021];9(6):e100261. Disponible en: https://doi.org/10.1371/journal.pone.0100261
6. Montani D, Lau EM, Dorfmüller P, Girerd B, Jaïs X, Savale L, et al. Pulmonary veno-occlusive disease. Eur Respir J. 2016;47(5):1518-34. DOI: https://doi.org/10.1183/13993003.00026-2016
7. Tenorio J, Navas P, Barrios E, Fernández L, Nevado J, Quezada CA, et al. A founder EIF2AK4 mutation causes an aggressive form of pulmonary arterial hypertension in Iberian Gypsies. Clin Genet. 2015;88(6):579-83. DOI: https://doi.org/10.1111/cge.12549
8. Nickel N, Golpon H, Greer M, Knudsen L, Olsson K, Westerkamp V, et al. The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension. Eur Respir J. 2012;39(3):589-96. DOI: https://doi.org/10.1183/09031936.00092311
9. Fang JC, DeMarco T, Givertz MM, Borlaug BA, Lewis GD, Rame JE, et al. World Health Organization Pulmonary Hypertension group 2: pulmonary hypertension due to left heart disease in the adult - A summary statement from the Pulmonary Hypertension Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2012;31(9):913-33. DOI: https://doi.org/10.1016/j.healun.2012.06.002
10. Pellegrini P, Rossi A, Pasotti M, Raineri C, Cicoira M, Bonapace S, et al. Prognostic relevance of pulmonary arterial compliance in patients with chronic heart failure. Chest. 2014;145(5):1064-70. DOI: https://doi.org/10.1378/chest.13-1510
11. Gómez-López EA. Hipertensión pulmonar asociada a enfermedad cardiaca izquierda. Enfoque diagnóstico y terapéutico. Rev Colomb Cardiol. 2017;24(Suppl 1):55-64. DOI: http://dx.doi.org/10.1016/j.rccar.2017.08.009
12. Barnett CF, Selby VM. Overview of WHO Group 2 pulmonary hypertension due to left heart disease. Advances in Pulmonary Hypertension. 2015;14(2):70-8. DOI: https://doi.org/10.21693/1933-088X-14.2.70
13. Seeger W, Adir Y, Barber? JA, Champion H, Coghlan JG, Cottin V, et al. Pulmonary hypertension in chronic lung diseases. J Am Coll Cardiol. 2013;62(25 Suppl):D109-16. DOI: https://doi.org/10.1016/j.jacc.2013.10.036
14. Barber? JA, Blanco I. Management of Pulmonary Hypertension in Patients with Chronic Lung Disease. Curr Hypertens Rep. 2015;17(8):62. DOI: https://doi.org/10.1007/s11906-015-0574-9
15. López Guide MJ, Pérez de la Sota E, Forteza Gil A, Centeno Rodríguez J, Eixeres A, Velázquez MT, et al. Pulmonary thromboendarterectomy in 106 patients with chronic thromboembolic pulmonary hypertension. Arch Bronconeumol. 2015;51(10):502-8. DOI: http://dx.doi.org/10.1016/j.arbres.2014.11.012
16. Coronel ML, Chamorro N, Blanco I, Amado V, Del Pozo R, Pomar JL, et al. Medical and surgical management for chronic thromboembolic pulmonary hypertension: a single center experience. Arch Bronconeumol. 2014;50(12):521-7. DOI: https://doi.org/10.1016/j.arbres.2014.04.011
17. Escribano-Subías P, Del Pozo R, Román-Broto A, Domingo Morera JA, Lara-Padrón A, Elías Hernández T, et al. Management and outcomes in chronic thromboembolic pulmonary hypertension: From expert centers to a nationwide perspective. Int J Cardiol. 2016;203:938-44. DOI: https://doi.org/10.1016/j.ijcard.2015.11.039
18. Ghofrani HA, D'Armini AM, Grimminger F, Hoeper MM, Jansa P, Kim NH, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med. 2013;369(4):319-29. DOI: https://doi.org/10.1056/nejmoa1209657
19. Ghofrani HA, Simonneau G, D'Armini AM, Fedullo P, Howard LS, Jaïs X, et al. Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study. Lancet Respir Med. 2017;5(10):785-94. DOI: https://doi.org/10.1016/s2213-2600(17)30305-3
20. Jaïs X, D'Armini AM, Jansa P, Torbicki A, Delcroix M, Ghofrani HA, et al. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. J Am Coll Cardiol. 2008;52(25):2127-34. DOI: https://doi.org/10.1016/j.jacc.2008.08.059
21. Olsson KM, Wiedenroth CB, Kamp JC, Breithecker A, Fuge J, Krombach GA, et al. Balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension: the initial German experience. Eur Respir J [Internet]. 2017 [citado 15 Ene 2021];49(6):1602409. Disponible en: https://doi.org/10.1183/13993003.02409-2016
22. Velázquez Martín M, Albarrán González-Trevilla A, Alonso Charterina S, García Tejada J, Cortina Romero JM, Escribano Subías P. Angioplastia pulmonar con balón en la hipertensión pulmonar tromboembólica crónica no operable. Experiencia inicial en España en una serie de 7 pacientes. Rev Esp Cardiol. 2015;68(6):535-7. DOI: https://doi.org/10.1016/j.rec.2015.02.004
23. Phan K, Jo HE, Xu J, Lau EM. Medical Therapy Versus Balloon Angioplasty for CTEPH: A Systematic Review and Meta-Analysis. Heart Lung Circ. 2018;27(1):89-98. DOI: https://doi.org/10.1016/j.hlc.2017.01.016
24. Barber? JA, Escribano P, Morales P, Gómez MA, Oribe M, Martínez A, et al. Estándares asistenciales en hipertensión pulmonar: Documento de consenso elaborado por la Sociedad Española de Neumología y Cirugía Torácica (SEPAR) y la Sociedad Española de Cardiología (SEC). Arch Bronconeumol. 2008;44(2):87-99. DOI: https://doi.org/10.1157/13115748
25. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med. 1992;327(2):76-81. DOI: https://doi.org/10.1056/nejm199207093270203
26. McLaughlin VV, Benza RL, Rubin LJ, Channick RN, Voswinckel R, Tapson VF, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol. 2010;55(18):1915-22. DOI: https://doi.org/10.1016/j.jacc.2010.01.027
27. Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galiè N, et al. Selexipag for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2015;373(26):2522-33. DOI: https://doi.org/10.1056/nejmoa1503184
28. Sandoval J, Gaspar J, Peña H, Santos LE, Córdova J, del Valle K, et al. Effect of atrial septostomy on the survival of patients with severe pulmonary arterial hypertension. Eur Respir J. 2011;38(6):1343-8. DOI: https://doi.org/10.1183/09031936.00072210
29. Galiè N, Barber? JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, et al. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. N Engl J Med. 2015;373(9):834-44. DOI: https://doi.org/10.1056/nejmoa1413687
30. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996;334(5):296-301. DOI: https://doi.org/10.1056/nejm199602013340504
31. Sitbon O, Jaïs X, Savale L, Cottin V, Bergot E, Macari EA, et al. Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study. Eur Respir J. 2014;43(6):1691-7. DOI: https://doi.org/10.1183/09031936.00116313
32. Badesch DB, Abman SH, Ahearn GS, Barst RJ, McCrory DC, Simonneau G, et al. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004;126(1 Suppl):35S-62S. DOI: https://doi.org/10.1378/chest.126.1_suppl.35s
33. Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Hervé P, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol. 2002;40(4):780-8. DOI: https://doi.org/10.1016/s0735-1097(02)02012-0
34. Sitbon O, McLaughlin VV, Badesch DB, Barst RJ, Black C, Galiè N, et al. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol. Thorax. 2005;60(12):1025-30. DOI: https://doi.org/10.1136/thx.2005.040618
35. Wensel R, Opitz CF, Anker SD, Winkler J, Höffken G, Kleber FX, et al. Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing. Circulation. 2002;106(3):319-24. DOI: https://doi.org/10.1161/01.cir.0000022687.18568.2a
36. Sun XG, Hansen JE, Oudiz RJ, Wasserman K. Exercise pathophysiology in patients with primary pulmonary hypertension. Circulation. 2001;104(4):429-35. DOI: https://doi.org/10.1161/hc2901.093198
37. Nagaya N, Nishikimi T, Uematsu M, Satoh T, Kyotani S, Sakamaki F, et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation. 2000;102(8):865-70. DOI: https://doi.org/10.1161/01.cir.102.8.865
38. Fijalkowska A, Kurzyna M, Torbicki A, Szewczyk G, Florczyk M, Pruszczyk P, et al. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. Chest. 2006;129(5):1313-21. DOI: https://doi.org/10.1378/chest.129.5.1313
39. Raymond RJ, Hinderliter AL, Willis PW, Ralph D, Caldwell EJ, Williams W, et al. Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. J Am Coll Cardiol. 2002;39(7):1214-9. DOI: https://doi.org/10.1016/s0735-1097(02)01744-8
40. Forfia PR, Fisher MR, Mathai SC, Housten-Harris T, Hemnes AR, Borlaug BA, et al. Tricuspid annular displacement predicts survival in pulmonary hypertension. Am J Respir Crit Care Med. 2006;174(9):1034-41. DOI: https://doi.org/10.1164/rccm.200604-547oc
41. McLaughlin VV, Sitbon O, Badesch DB, Barst RJ, Black C, Galiè N, et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J. 2005;25(2):244-9. DOI: https://doi.org/10.1183/09031936.05.00054804
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes:- Los autores/as conservarán sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia de reconocimiento de Creative Commons que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación esta revista.
- Los autores/as podrán adoptar otros acuerdos de licencia no exclusiva de distribución de la versión de la obra publicada (p. ej.: depositarla en un archivo telemático institucional o publicarla en un volumen monográfico) siempre que se indique la publicación inicial en esta revista.
